Metformin and Prostate Cancer: What is the Evidence?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.29315/gm.v1i1.653 |
Resumo: | INTRODUCTION: Prostate cancer (PCa) is the most prevalent cancer in males worldwide. Despite therapeutic advances, up to 30%-50% of patients experience recurrence. In recent years, the antineoplastic potential of metformin has been described in the incidence and prognosis of PCa. The aim of this review will be to assess the evidence on the use of metformin to reduce recurrence and increase survival in patients with PCa.METHODS: The authors carried out a literature search in evidence-based medicine databases, including articles published between 01/2010 and 05/2022, in Portuguese and English. The MeSH terms used were “metformin”, “prostate cancer” and “therapy”. The level of evidence and strength of recommendation were assigned according to the Strength Of Recommendation Taxonomy (SORT) scale.RESULTS: In the initial search, 17 articles were obtained, of which 3 meta-analyses were selected to carry out this review. All meta-analyses revealed a decrease in PCa recurrence in patients using metformin. The 3 meta-analyses also found an improvement in overall and PCa-specific survival in patients treated with metformin, however, only one of them showed a statistically significant association.CONCLUSION: This review concluded, with a strength of recommendation B, that the use of metformin may have a positive impact on reducing recurrence and improving the survival of patients with PCa. However, it will be necessary to carry out more studies, with greater robustness and quality, to confirm this relationship. |
id |
RCAP_83961700aa892e0eae03fd6c9d45747f |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/653 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
|
spelling |
Metformin and Prostate Cancer: What is the Evidence?Metformina e Cancro da Próstata: Qual a Evidência?Metformina/usoterapêuticoNeoplasias da Próstata/mortalidadeNeoplasias da Próstata/ tratamento farmacológicoMetformin/therapeutic useProstatic Neoplasms/drug therapyProstatic Neoplasms/mortalityINTRODUCTION: Prostate cancer (PCa) is the most prevalent cancer in males worldwide. Despite therapeutic advances, up to 30%-50% of patients experience recurrence. In recent years, the antineoplastic potential of metformin has been described in the incidence and prognosis of PCa. The aim of this review will be to assess the evidence on the use of metformin to reduce recurrence and increase survival in patients with PCa.METHODS: The authors carried out a literature search in evidence-based medicine databases, including articles published between 01/2010 and 05/2022, in Portuguese and English. The MeSH terms used were “metformin”, “prostate cancer” and “therapy”. The level of evidence and strength of recommendation were assigned according to the Strength Of Recommendation Taxonomy (SORT) scale.RESULTS: In the initial search, 17 articles were obtained, of which 3 meta-analyses were selected to carry out this review. All meta-analyses revealed a decrease in PCa recurrence in patients using metformin. The 3 meta-analyses also found an improvement in overall and PCa-specific survival in patients treated with metformin, however, only one of them showed a statistically significant association.CONCLUSION: This review concluded, with a strength of recommendation B, that the use of metformin may have a positive impact on reducing recurrence and improving the survival of patients with PCa. However, it will be necessary to carry out more studies, with greater robustness and quality, to confirm this relationship.INTRODUÇÃO: O cancro da próstata (CaP) é a neoplasia mais prevalente no sexo masculino a nível mundial. Apesar dos avanços terapêuticos, até 30%-50% dos doentes apresentam recorrência da mesma. Nos últimos anos, tem sido descrito o potencial anti-neoplásico da metformina, nomeadamente na incidência e prognóstico do CaP. O objetivo desta revisão será avaliar a evidência sobre o uso da metformina na redução da recorrência e no aumento da sobrevivência dos doentes com CaP.MÉTODOS: As autoras realizaram uma pesquisa bibliográfica em bases de dados de medicina baseada na evidência, tendo sido incluídos artigos publicados entre 01/2010 e 05/2022, em idioma português e inglês. Os termos MeSH utilizados foram “metformin”, “prostate cancer” e “therapy”. A atribuição de nível de evidência e força de recomendação foi realizada atendendo à escala Strength Of Recommendation Taxonomy (SORT).RESULTADOS: Na pesquisa inicial obtiveram-se 17 artigos, dos quais foram selecionadas 3 meta-análises para a realização desta revisão. Todas as meta-análises revelaram uma diminuição da recorrência do CaP nos utentes a utilizar metformina. As 3 meta-análises verificaram ainda uma melhoria da sobrevivência global e específica por CaP nos utentes sob tratamento com metformina, no entanto, apenas uma delas demonstrou associação estatisticamente significativa.CONCLUSÃO: Esta revisão concluiu, com uma força de recomendação B, que a utilização de metformina poderá ter impacto positivo na redução da recorrência e na melhoria da sobrevivência dos doentes com CaP. No entanto, será necessário realizar mais estudos, com maior robustez e qualidade, para confirmar esta relação.CUF Academic Center2023-03-20info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.29315/gm.v1i1.653https://doi.org/10.29315/gm.v1i1.653Gazeta Médica; NUMBER 1 · VOLUME 10 · JANUARY/MARCH 2023; 24-30Gazeta Médica; NÚMERO 1 · VOLUME 10 · JANEIRO/MARÇO 2023; 24-302184-06282183-813510.29315/gm.v10i1reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.gazetamedica.pt/index.php/gazeta/article/view/653https://www.gazetamedica.pt/index.php/gazeta/article/view/653/414Copyright (c) 2023 Gazeta Médicahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessTeixeira da Silva Vieira, CatarinaMonteiro, Ana LuísaCampos, CatarinaChão, IsabelGonçalves, Joana2023-04-01T04:45:28ZPortal AgregadorONG |
dc.title.none.fl_str_mv |
Metformin and Prostate Cancer: What is the Evidence? Metformina e Cancro da Próstata: Qual a Evidência? |
title |
Metformin and Prostate Cancer: What is the Evidence? |
spellingShingle |
Metformin and Prostate Cancer: What is the Evidence? Teixeira da Silva Vieira, Catarina Metformina/usoterapêutico Neoplasias da Próstata/mortalidade Neoplasias da Próstata/ tratamento farmacológico Metformin/therapeutic use Prostatic Neoplasms/drug therapy Prostatic Neoplasms/mortality |
title_short |
Metformin and Prostate Cancer: What is the Evidence? |
title_full |
Metformin and Prostate Cancer: What is the Evidence? |
title_fullStr |
Metformin and Prostate Cancer: What is the Evidence? |
title_full_unstemmed |
Metformin and Prostate Cancer: What is the Evidence? |
title_sort |
Metformin and Prostate Cancer: What is the Evidence? |
author |
Teixeira da Silva Vieira, Catarina |
author_facet |
Teixeira da Silva Vieira, Catarina Monteiro, Ana Luísa Campos, Catarina Chão, Isabel Gonçalves, Joana |
author_role |
author |
author2 |
Monteiro, Ana Luísa Campos, Catarina Chão, Isabel Gonçalves, Joana |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Teixeira da Silva Vieira, Catarina Monteiro, Ana Luísa Campos, Catarina Chão, Isabel Gonçalves, Joana |
dc.subject.por.fl_str_mv |
Metformina/usoterapêutico Neoplasias da Próstata/mortalidade Neoplasias da Próstata/ tratamento farmacológico Metformin/therapeutic use Prostatic Neoplasms/drug therapy Prostatic Neoplasms/mortality |
topic |
Metformina/usoterapêutico Neoplasias da Próstata/mortalidade Neoplasias da Próstata/ tratamento farmacológico Metformin/therapeutic use Prostatic Neoplasms/drug therapy Prostatic Neoplasms/mortality |
description |
INTRODUCTION: Prostate cancer (PCa) is the most prevalent cancer in males worldwide. Despite therapeutic advances, up to 30%-50% of patients experience recurrence. In recent years, the antineoplastic potential of metformin has been described in the incidence and prognosis of PCa. The aim of this review will be to assess the evidence on the use of metformin to reduce recurrence and increase survival in patients with PCa.METHODS: The authors carried out a literature search in evidence-based medicine databases, including articles published between 01/2010 and 05/2022, in Portuguese and English. The MeSH terms used were “metformin”, “prostate cancer” and “therapy”. The level of evidence and strength of recommendation were assigned according to the Strength Of Recommendation Taxonomy (SORT) scale.RESULTS: In the initial search, 17 articles were obtained, of which 3 meta-analyses were selected to carry out this review. All meta-analyses revealed a decrease in PCa recurrence in patients using metformin. The 3 meta-analyses also found an improvement in overall and PCa-specific survival in patients treated with metformin, however, only one of them showed a statistically significant association.CONCLUSION: This review concluded, with a strength of recommendation B, that the use of metformin may have a positive impact on reducing recurrence and improving the survival of patients with PCa. However, it will be necessary to carry out more studies, with greater robustness and quality, to confirm this relationship. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-03-20 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.29315/gm.v1i1.653 https://doi.org/10.29315/gm.v1i1.653 |
url |
https://doi.org/10.29315/gm.v1i1.653 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.gazetamedica.pt/index.php/gazeta/article/view/653 https://www.gazetamedica.pt/index.php/gazeta/article/view/653/414 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2023 Gazeta Médica http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 Gazeta Médica http://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
CUF Academic Center |
publisher.none.fl_str_mv |
CUF Academic Center |
dc.source.none.fl_str_mv |
Gazeta Médica; NUMBER 1 · VOLUME 10 · JANUARY/MARCH 2023; 24-30 Gazeta Médica; NÚMERO 1 · VOLUME 10 · JANEIRO/MARÇO 2023; 24-30 2184-0628 2183-8135 10.29315/gm.v10i1 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1777302435028533248 |